Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Free Cash Flow (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Free Cash Flow for 11 consecutive years, with -$69.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 18.72% to -$69.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$395.9 million, a 13.28% decrease, with the full-year FY2025 number at -$395.9 million, down 13.28% from a year prior.
  • Free Cash Flow was -$69.4 million for Q4 2025 at Intellia Therapeutics, up from -$76.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$52.5 million in Q2 2021 to a low of -$149.0 million in Q1 2025.
  • A 5-year average of -$86.3 million and a median of -$85.0 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 193.34% in 2021, then surged 38.74% in 2024.
  • Intellia Therapeutics' Free Cash Flow stood at -$57.5 million in 2021, then tumbled by 55.27% to -$89.3 million in 2022, then dropped by 18.11% to -$105.5 million in 2023, then increased by 19.04% to -$85.4 million in 2024, then grew by 18.72% to -$69.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Free Cash Flow are -$69.4 million (Q4 2025), -$76.9 million (Q3 2025), and -$100.5 million (Q2 2025).